Thorough and intensive QTc Studies

Richmond Pharmacology has globally recognised expertise in cardiac safety, intensive ECG studies, cardiology overreading, statistical analysis, reporting and publishing.

We are proud of our successful track record which is demonstrated in our published studies.

We provide sponsors with FDA compliant analysis methods, and the option to include a non-pharmacological method of proving assay sensitivity. Our unique and innovative approach means that we conduct our studies and prove assay sensitivity as a standard feature. This has provided quality data in many Japanese bridging, SAD and MAD studies, eliminating the need for a dedicated TQT study.

x

Examples of our credentials in TQT and QTc Studies

Food effect on QT interval. Our research has confirmed food impacts cardiac repolarisation by shortening the J-T peak. This can be used in our studies as a non-pharmacological method of proving assay sensitivity. Learn more here.

Sex hormones and the QT Interval. Research funded by Richmond Pharmacology identified a significant influence of estradiol on QTcF suggesting a menstrual cycle could influence the QTc. Learn more here.

Short start-up times of 4-6 weeks, rapid data readout

Our study data is well respected by regulators such as FDA, EMA and PMDA. Our statistical team specialise in statistical analysis concentration effect modelling, reporting, and publishing.

Get in touch today

Why choose Richmond Pharmacology for TQT & QTc Studies

TAP OR CLICK A BLOCK BELOW TO LEARN MORE

Low data variability

Our core ECG laboratory provides a centralised system for all our studies.

Read more +

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment.

Read more +

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London.

Read more +

Our in-house cardiac experts include Professor John Camm and Dr Jorg Taubel. Together, they ensure your QTc study is best-in-class. Meet the team.

Latest news

Single-dose gene silencing cure for fatal heart disease comes one step closer

March 20, 2024
Richmond is delighted to be part of the first large-scale in-human trial of a genetic cure for ATTR Amyloidosis
Read more

How Does Social Time Contribute to a Positive Workplace Culture?

March 13, 2023
Read the blog by Richmond Pharmacology’s Chair of the Social Committee and Head of Marketing, Elizabeth Romano about how being social improves organisational culture and embeds the core values.
Read more

Events

ISA Symposium 2024

29-30 May 2024 
We will be attending the XIX International Symposium on Amyloidosis, taking place in Rochester, Minesota
View event